"The Cholesterol Conspiracy" Revised 2nd Edition
How Pharmaceutical Companies Continue to Hide the Truth About Cholesterol.
Includes the Newest Research Findings Showing the Effectiveness of Nutritional Supplements for the Prevention of Heart Disease and Stroke.
This audiobook is read by the author, Ladd R. McNamara, M.D.
Copies of the Cholestrol Conspiracy are available!
Audio Book and Paper Back versions are available at http://www.laddmcnamara.com/bookstore along with other books written by Dr. McNamara.
In this episode Dr. McNamara discusses homocysteine blood levels and it’s association with heart disease.
- Chapter 9: Homocysteine Oxidizes Both LDL Cholesterol and the Arterial Walls
- Chapter 10: Pharmaceutical Companies Conspire to Hide the Truth
- Chapter 11: The Discovery of the Association Between Homocysteine and Heart Disease
Chapter Excerpts
Inasmuch as the medical dogma was that high cholesterol caused heart disease, naturally Dr. McCully’s research and findings showing otherwise were blackballed by the pharmaceutical industry.
Homocysteine is second only to cigarette smoking in its oxidative destruction. The combination of oxidized LDL cholesterol and a damaged arterial lining is what causes LDL cholesterol to stick to the arteries, independent of whether the LDL cholesterol level is normal or not.
"I realized immediately that this was a critical case because if this boy had arteriosclerosis, it would prove that no matter what the enzyme defect and no matter what the metabolic pattern, patients with inherited diseases causing homocystinuria also developed arteriosclerosis. Because of this I could attribute formation of the plaques to elevated homocysteine levels."
Kilmer McCully, M.D.
"They told me later they didn’t want to have Harvard or Massachusetts General Hospital associated with my theory because it appeared to contradict the conventional wisdom that cholesterol and fats were the causes of heart disease."
Kilmer McCully, M.D.
Chapter References
- 10: Haim M, et al. Serum Homocysteine and Long-Term Risk of Myocardial Infarction and Sudden Death in Patients with Coronary Heart Disease. Cardiology. 2006 Jun 6;107(1):52-56.
Podcast: Play in new window
| Download
In this episode Dr. McNamara will discuss the true cause of heart disease and stroke
- Chapter 8: The True Cause of Heart Disease and Stroke
Chapter Excerpts
LDL cholesterol only becomes “bad” when it is damaged by oxidative free radicals. Only the damaged, or oxidized form of LDL cholesterol sticks to the arterial walls to initiate the formation of plaque.
The push is so strong by pharmaceutical companies to have doctors prescribe statin drugs, that without even a shred of evidence to support the benefits, diabetics with normal cholesterol levels are told to go on statin drugs “ just in case” they might be found to be helpful some day, and the consequences be damned!
Chapter References
- 2: Schroecksnadel K, et al. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol. 2006 Jul;4(3):205-13.
- 3: Gibelin P, et al. Prognostic value of homocysteinemia in patients with congestive heart failure. Clin Chem Lab Med. 2006;44(7):813-6.
- 4: Van Oijen MG, et al. Hyperhomocysteinaemia and Vitamin B12 Deficiency: The Long-Term Effects in Cardiovascular Disease. Cardiology. 2006 Jun 6;107(1):57-62 [Epub ahead of print].
- 5: Haim M, et al. Serum Homocysteine and Long-Term Risk of Myocardial Infarction and Sudden Death in Patients with Coronary Heart Disease. Cardiology. 2006 Jun 6;107(1):52-56.
- 6: Laaksonen R, et al. High oxidized LDL and elevated plasma homocysteine contribute to the early reduction of myocardial flow reserve in healthy adults. Eur J Clin Invest. 2002 Nov;32(11):795-802.
- 7: Troughton JA, et al. Homocysteine and coronary heart disease risk in the PRIME study. Atherosclerosis. 2006 Jun 13; [Epub ahead of print].
- 8: Tsimikas, S, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005 Jul 7;353(1):9-11.
- 9: Anselmi M, et al. Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis. 2006 Mar;185(1):114-20.
Podcast: Play in new window
| Download
In this episode Dr. McNamara discusses how the Pharmaceutical Industry influences medical education and the myth that high cholesterol is the primary cause of heart disease.
- Chapter 5: How the Pharmaceutical Industry Influences Medical Education
- Chapter 6: The Myth that High Cholesterol Causes Heart Disease
- Chapter 7: The Number One Cause of Death in the United States
Chapter Excerpts
It was only about ten years ago that the Surgeon General declared that 68% of all disease is caused by diet.
That would make a poor diet the number one cause of ill health in the United States, not the omission of prescription drugs.
A poor diet is defined as a lack of vitamins, minerals, antioxidants, essential fatty acids.
As there was more money to be made from pharmaceutical development, the campaign to produce cholesterol-lowering drugs kicked into high gear, despite the lack of evidence showing that lowering cholesterol reduced the risk of death from heart disease.
Podcast: Play in new window
| Download
This episode introduces the book and discusses Atherosclerosis, or hardening of the arteries.
- Chapter 1: Introduction
- Chapter 2: What is Atherosclerosis?
- Chapter 3: Incidence of Atherosclerosis
- Chapter 4: Causes and/or Risk Factors For Atherosclerosis
Chapter Excerpts
"All truth passes through three stages.
First, it is ridiculed.
Second, it is violently opposed.
Third, it is accepted as being self-evident."
German philosopher, Arthur Schopenhauer (1788 - 1860)
The "cholesterol conspiracy" is the perpetuated dogma by pharmaceutical companies and willing accomplices in medical organizations and the media that lowering LDL cholesterol is the solution to reducing heart disease and stroke.
Chapter References
- 1: Bhatt DL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006 Jan 11;295(2):180-9.
Podcast: Play in new window
| Download
